argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for argenx SE (ARGX)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | GlobeNewsWire
2 weeks ago | Benzinga
2 weeks ago | GlobeNewsWire
3 weeks ago | GlobeNewsWire
a month ago | GlobeNewsWire
a month ago | GlobeNewsWire
2 months ago | Barrons
2 months ago | Zacks Investment Research
2 months ago | GlobeNewsWire
2 months ago | GlobeNewsWire